Pulmonary Rehabilitation in Patients with COVID-19—A Protocol for Systematic Review and Meta-Analysis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Aims
2.1.1. Primary Aim
2.1.2. Review Questions
2.2. Design
2.2.1. Inclusion and Exclusion Criteria
Types of Studies
Types of Participants
Types of Interventions
Types of Outcomes
2.3. Search Methods
2.3.1. Search Strategy
Electronic Searches
Additional Resources
2.3.2. Study Selection
2.3.3. Data Extraction
2.4. Quality Appraisal
2.5. Data Synthesis
2.5.1. Meta-Analysis
2.5.2. Descriptive Review
2.5.3. Subgroup Analysis
2.5.4. Sensitivity Analysis
2.6. Assessment of Publication Biases
2.7. Ethical Considerations
3. Results
4. Discussion
5. Limitations
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Appendix A. General Information
General Information | |||
Date form completed | |||
First Author | |||
Study title | |||
DOI number | |||
Year of publication | |||
Published trial | YES [ ] | NO [ ] | |
Publication type | |||
Author contacted | YES [ ] | NO [ ] | time |
Notes: |
Appendix B. Trial Eligibility
Study Characteristics | Review Inclusion Criteria | Yes/No/Unclear | Location in Text |
Type of study | Randomized trial | ||
Other design (specify): | |||
Participants | 1. COVID-19 patients | ||
2. Other: | |||
Intervention | Treatment in any type of PR | ||
Decision: | Included [ ]/excluded [ ] | ||
Reason for exclusion | |||
Notes: |
Appendix C. Methods
Descriptions as Stated in Report/Paper | Location in Text | ||||
Country/Countries | |||||
Aim of study | Aim: Not clearly defined [ ] | ||||
Start date | |||||
End date | |||||
Total number of groups | |||||
Number of participants in each group | Intervention: ____ Control: _____ Other: ______ | ||||
Number of participants that were analyzed | Intervention: ____ Control: _____ Other:______ | ||||
Duration of participation | |||||
What was/were the primary outcome(s) | 1a. | 1b. | 1c. | ||
What was/were the secondary outcome(s) | 2a. | 2b. | 2c. | ||
Time points where outcomes were measured | Primary outcomes: | ||||
1a. | 1b. | 1c. | |||
Secondary outcomes: | |||||
2a. | 2b. | 2c. | |||
Notes: |
Appendix D. Groups
Intervention Group (PR) | Comparison Group | |||||
Description as Stated in Report/Paper | Location in Text | Description as Stated in Report/Paper | Location in Text | |||
Group name | ||||||
Age | Mean: | Age | Mean: | |||
Median: | Median: | |||||
SD: | SD: | |||||
Range: | Range: | |||||
IQR: | IQR: | |||||
Sex | Number of Males [ ] | Sex | Number of Males [ ] | |||
Number of Females [ ] | Number of Females [ ] | |||||
Race/Ethnicity | Race/Ethnicity | |||||
Severity of illness | Severity of illness | |||||
Comorbidities | Comorbidities | |||||
Other treatment received (additional to PR) | Control intervention | |||||
Types of PR | ||||||
Frequency/intensity | Frequency/intensity | |||||
Duration | Duration | |||||
Co-interventions | ||||||
Notes: |
Appendix E. Outcomes
Outcome 1 | Outcome 2 | Outcome 3 | ||||
Description as Stated in Report/Paper | Location in Text | Description as Stated in Report/Paper | Location in Text | Description as Stated in Report/Paper | Location in Text | |
Outcome name | ||||||
Time points measured | ||||||
Time points reported | ||||||
Outcome definition | ||||||
Person measuring/reporting | ||||||
Unit of measurement | ||||||
Scales: upper and lower limits | ||||||
Is outcome/tool validated? | Yes [ ] No [ ] Unclear [ ] | Yes [ ] No [ ] Unclear [ ] | Yes [ ] No [ ] Unclear [ ] | |||
Imputation of missing data | ||||||
Assumed risk estimate | ||||||
Notes: |
References
- WHO Coronavirus (COVID-19) Dashboard, COVID-19 Situation Update Worldwide. 2022. Available online: https://covid19.who.int/ (accessed on 2 August 2022).
- Makaronidis, J.; Mok, J.; Balogun, N.; Magee, C.G.; Omar, R.Z.; Carnemolla, A.; Batterham, R.L. Seroprevalence of SARS-CoV-2 antibodies in people with an acute loss in their sense of smell and/or taste in a community-based population in London, UK: An observational cohort study. PLoS Med. 2020, 17, e1003358. [Google Scholar] [CrossRef]
- Spruit, M.A.; Singh, S.J.; Garvey, C.; ZuWallack, R.; Nici, L.; Rochester, C.; Hill, K.; Holland, A.E.; Lareau, S.C.; Man, W.D.-C.; et al. An official American Thoracic Society/European Respiratory Society statement: Key concepts and advances in pulmonary rehabilitation. Am. J. Respir. Crit. Care Med. 2013, 188, e13–e64. [Google Scholar] [CrossRef] [Green Version]
- Holland, A.E.; Mahal, A.; Hill, C.J.; Lee, A.L.; Burge, A.T.; Cox, N.S.; Moore, R.; Nicolson, C.; O’Halloran, P.; Lahham, A.; et al. Home-based rehabilitation for COPD using minimal resources: A randomised, controlled equivalence trial. Thorax 2017, 72, 57–65. [Google Scholar] [CrossRef] [Green Version]
- Vasilopoulou, M.; Papaioannou, A.I.; Kaltsakas, G.; Louvaris, Z.; Chynkiamis, N.; Spetsioti, S.; Kortianou, E.; Genimata, S.A.; Palamidas, A.; Kostikas, K.; et al. Home-based maintenance tele-rehabilitation reduces the risk for acute exacerbations of COPD, hospitalisations and emergency department visits. Eur. Respir. J. 2017, 49, 1602129. [Google Scholar] [CrossRef] [Green Version]
- Farmer, A.; Williams, V.; Velardo, C.; Shah, S.A.; Yu, L.-M.; Rutter, H.; Jones, L.; Williams, N.; Heneghan, C.; Price, J.; et al. Self-management support using a digital health system compared with usual care for chronic obstructive pulmonary disease: Randomized controlled trial. J. Med. Internet Res. 2017, 19, e144. [Google Scholar] [CrossRef] [Green Version]
- Bernocchi, P.; Vitacca, M.; la Rovere, M.T.; Volterrani, M.; Galli, T.; Baratti, D.; Paneroni, M.; Campolongo, G.; Sposato, B.; Scalvini, S. Home-based telerehabilitation in older patients with chronic obstructive pulmonary disease and heart failure: A randomised controlled trial. Age Ageing 2018, 47, 82–88. [Google Scholar] [CrossRef] [Green Version]
- Wootton, S.L.; Hill, K.; Alison, J.A.; Ng, L.W.C.; Jenkins, S.; Eastwood, P.R.; Hillman, D.R.; Jenkins, C.; Spencer, L.; Cecins, N.; et al. Effects of ground-based walking training on daily physical activity in people with COPD: A randomised controlled trial. Respir. Med. 2017, 132, 139–145. [Google Scholar] [CrossRef] [Green Version]
- Holland, A.E.; Cox, N.S.; Houchen-Wolloff, L.; Rochester, C.L.; Garvey, C.; ZuWallack, R.; Nici, L.; Limberg, T.; Lareau, S.C.; Yawn, B.P.; et al. Defining Modern Pulmonary Rehabilitation. An Official American Thoracic Society Workshop Report. Ann. Am. Thorac. Soc. 2021, 18, e12–e29. [Google Scholar] [CrossRef]
- Vestbo, J.; Hurd, S.S.; Agustí, A.G.; Jones, P.W.; Vogelmeier, C.; Anzueto, A.; Barnes, P.J.; Fabbri, L.M.; Martinez, F.J.; Nishimura, M.; et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2013, 187, 347–365. [Google Scholar] [CrossRef]
- McCarthy, B.; Casey, D.; Devane, D.; Murphy, K.; Murphy, E.; Lacasse, Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2015, CD003793. [Google Scholar] [CrossRef]
- Puhan, M.A.; Gimeno-Santos, E.; Cates, C.J.; Troosters, T. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2016, 12, CD005305. [Google Scholar] [CrossRef] [PubMed]
- Dowman, L.; Hill, C.J.; May, A.; Holland, A.E. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst. Rev. 2021, 2, CD006322. [Google Scholar] [CrossRef] [PubMed]
- Lee, A.L.; Hill, C.J.; McDonald, C.F.; Holland, A.E. Pulmonary rehabilitation in individuals with non–cystic fibrosis bronchiectasis: A systematic review. Arch. Phys. Med. Rehabil. 2017, 98, 774–782.e1. [Google Scholar] [CrossRef] [PubMed]
- Morris, N.R.; Kermeen, F.D.; Holland, A.E. Exercise-based rehabilitation programmes for pulmonary hypertension. Cochrane Database Syst. Rev. 2017, 1, CD011285. [Google Scholar] [CrossRef] [Green Version]
- Man, W.D.; Polkey, M.I.; Donaldson, N.; Gray, B.J.; Moxham, J. Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: Randomised controlled study. BMJ 2004, 329, 1209. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Macrea, M.; Oczkowski, S.; Rochwerg, B.; Branson, R.D.; Celli, B.; Coleman, J.M., III; Hess, D.R.; Knight, S.L.; Ohar, J.A.; Orr, J.E.; et al. Long-term noninvasive ventilation in chronic stable hypercapnic chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am. J. Respir. Crit. Care Med. 2020, 202, e74–e87. [Google Scholar] [CrossRef]
- Blanc, P.D.; Annesi-Maesano, I.; Balmes, J.R.; Cummings, K.J.; Fishwick, D.; Miedinger, D.; Murgia, N.; Naidoo, R.N.; Reynolds, C.J.; Sigsgaard, T.; et al. The occupational burden of nonmalignant respiratory diseases. An official American Thoracic Society and European Respiratory Society statement. Am. J. Respir. Crit. Care Med. 2019, 199, 1312–1334. [Google Scholar] [CrossRef]
- Alison, J.; McKeough, Z.; Johnston, K.; McNamara, R.; Spencer, L.; Jenkins, S.; Hill, C.; McDonald, V.; Frith, P.; Caferella, P.; et al. Pulmonary Rehabilitation Guidelines for Australia and New Zealand. Respirology 2017, 22, 800–819. [Google Scholar] [CrossRef] [Green Version]
- Gong, Y.; Chen, J.; Li, P. Chronic respiratory disease lung rehabilitation nursing expert consensus. Chin. J. Nurs. 2020, 55, 709–710. [Google Scholar]
- Gonzalez-Gerez, J.J.; Saavedra-Hernandez, M.; Anarte-Lazo, E.; Bernal-Utrera, C.; Perez-Ale, M.; Rodriguez-Blanco, C. Short-term effects of a respiratory telerehabilitation program in confined COVID-19 patients in the acute phase: A pilot study. Int. J. Environ. Res. Public Health 2021, 18, 7511. [Google Scholar] [CrossRef]
- Dun, Y.; Liu, C.; Ripley-Gonzalez, J.W.; Liu, P.; Zhou, N.; Gong, X.; You, B.; Du, Y.; Liu, J.; Li, B. Six-month outcomes and effect of pulmonary rehabilitation among patients hospitalized with COVID-19: A retrospective cohort study. Ann. Med. 2021, 53, 2099–2109. [Google Scholar] [CrossRef] [PubMed]
- Aytür, Y.K.; Köseoğlu, B.F.; Taşkıran, Ö.Ö.; Ordu-Gökkaya, N.K.; Delialioğlu, S.Ü.; Tur, B.S.; Sarikaya, S.; Şirzai, H.; Tiftik, T.T.; Alemdaroğlu, E.; et al. Pulmonary rehabilitation principles in SARS-CoV-2 infection (COVID-19): A guideline for the acute and subacute rehabilitation. Turk. J. Phys. Med. Rehabil. 2020, 66, 104–120. [Google Scholar] [CrossRef] [PubMed]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int. J. Surg. 2021, 88, 105906. [Google Scholar] [CrossRef]
- Bhimraj, A.; Morgan, R.L.; Shumaker, A.H.; Lavergne, V.; Baden, L.; Cheng, V.C.-C.; Edwards, K.M.; Gandhi, R.; Muller, W.J.; O’Horo, J.C. Infectious Diseases Society of America Guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19). Clin. Infect. Dis. 2020; ahead of print. [Google Scholar]
- National Health Commission; State Administration of Traditional Chinese Medicine. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia; Revised version 7; National Health Commission: Beijing, China; State Administration of Traditional Chinese Medicine: Guangzhou, China, 2020.
- Wells, G.A.; O’Connell, D.; Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analyses. Available online: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed on 19 February 2018).
- Sterne, J.A.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.-Y.; Corbett, M.S.; Eldridge, S.M.; et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 2019, 366, 14898. [Google Scholar] [CrossRef] [Green Version]
- Sterne, J.A.; Sutton, A.J.; Ioannidis, J.P.; Terrin, N.; Jones, D.R.; Lau, J.; Carpenter, J.; Rücker, G.; Harbord, R.M.; Schmid, C.H.; et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011, 343, d4002. [Google Scholar] [CrossRef] [Green Version]
- Cui, X.; Chen, W.; Zhou, H.; Gong, Y.; Zhu, B.; Lv, X.; Guo, H.; Duan, J.; Zhou, J.; Marcon, E.; et al. Pulmonary edema in COVID-19 patients: Mechanisms and treatment potential. Front. Pharmacol. 2021, 12, 1444. [Google Scholar] [CrossRef]
- Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020, 323, 1061–1069. [Google Scholar] [CrossRef]
- Rajagopal, K.; Keller, S.P.; Akkanti, B.; Bime, C.; Loyalka, P.; Cheema, F.H.; Zwischenberger, J.B.; el Banayosy, A.; Pappalardo, F.; Slaughter, M.S.; et al. Advanced pulmonary and cardiac support of COVID-19 patients: Emerging recommendations from ASAIO—A living working document. Circ. Heart Fail. 2020, 13, e007175. [Google Scholar] [CrossRef] [PubMed]
- Ikeda, S.; Misumi, T.; Izumi, S.; Sakamoto, K.; Nishimura, N.; Ro, S.; Fukunaga, K.; Okamori, S.; Tachikawa, N.; Miyata, N.; et al. Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: A multicenter, retrospective, propensity score-matched study. Sci. Rep. 2021, 11, 10727. [Google Scholar] [CrossRef]
- Nici, L.; Donner, C.; Wouters, E.; Zuwallack, R.; Ambrosino, N.; Bourbeau, J.; Carone, M.; Celli, B.; Engelen, M.; Fahy, B.; et al. American thoracic society/European respiratory society statement on pulmonary rehabilitation. Am. J. Respir. Crit. Care Med. 2006, 173, 1390–1413. [Google Scholar] [CrossRef]
- Park, S.; Kim, J.Y.; Lee, J.C.; Kim, H.R.; Song, S.; Kwon, H.; Ji, W.; Choi, C.M. Mobile phone app–based pulmonary rehabilitation for chemotherapy-treated patients with advanced lung cancer: Pilot study. JMIR mHealth uHealth 2019, 7, e11094. [Google Scholar] [CrossRef]
- Liu, X.L.; Tan, J.Y.; Wang, T.; Zhang, Q.; Zhang, M.; Yao, L.Q.; Chen, J.X. Effectiveness of home-based pulmonary rehabilitation for patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials. Rehabil. Nurs. 2014, 39, 36–59. [Google Scholar] [CrossRef] [PubMed]
- Grosbois, J.M.; Gicquello, A.; Langlois, C.; le Rouzic, O.; Bart, F.; Wallaert, B.; Chenivesse, C. Long-term evaluation of home-based pulmonary rehabilitation in patients with COPD. Int. J. Chronic Obstr. Pulm. Dis. 2015, 10, 2037. [Google Scholar]
- Vagaggini, B.; Costa, F.; Antonelli, S.; de Simone, C.; de Cusatis, G.; Martino, F.; Santerini, S.; Paggiaro, P. Clinical predictors of the efficacy of a pulmonary rehabilitation programme in patients with COPD. Respir. Med. 2009, 103, 1224–1230. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Scott, A.S.; Baltzan, M.A.; Fox, J.; Wolkove, N. Success in pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. Can. Respir. J. 2010, 17, 219–223. [Google Scholar] [CrossRef] [PubMed]
- Zhao, H.-M.; Xie, Y.-X.; Wang, C.; Chinese Association of Rehabilitation Medicine; Respiratory Rehabilitation Committee of Chinese Association of Rehabilitation Medicine; Cardiopulmonary Rehabilitation Group of Chinese Society of Physical Medicine. Recommendations for respiratory rehabilitation in adults with coronavirus disease 2019. Chin. Med. J. 2020, 133, 1595–1602. [Google Scholar] [CrossRef] [PubMed]
- Carda, S.; Invernizzi, M.; Bavikatte, G.; Bensmaïl, D.; Bianchi, F.; Deltombe, T.; Draulans, N.; Esquenazi, A.; Francisco, G.E.; Gross, R.; et al. The role of physical and rehabilitation medicine in the COVID-19 pandemic: The clinician’s view. Ann. Phys. Rehabil. Med. 2020, 63, 554. [Google Scholar] [CrossRef]
- British Thoracic Society. Guidance on Adapted Delivery of Pulmonary Rehabilitation to Patients Surviving COVID-19. 2020. Available online: https://www.brit-thoracic.org.uk/covid-19/covid-19-information-for-the-respiratory-community (accessed on 13 January 2022).
Outcomes | Assessments and Indexes |
---|---|
Primary outcomes | |
Pulmonary function | Pulmonary function tests (FVC, FEV1, PEF, VC) |
Exercise capacity | Six-minute walk test, cardiopulmonary exercise testing (VO2max, peak VO2) |
Dyspnea | Multidimensional dyspnea -12 scale, Borg scale |
Health-related quality of life | Quality-of-life inventory |
Secondary outcomes | |
The number of hospitalizations and days in the hospital | Admission notes, progress notes |
Anxiety and depression | The hospital anxiety and depression scale |
Strength and endurance | Muscle strength and endurance tests (HGS, 1RM, sit-ups) |
Sleep disorders | Pittsburgh sleep quality index |
Fatigue | Multidimensional fatigue inventory |
Anorexia | Anorexia inventory |
Blood pressure | Sphygmomanometer |
Heart rate | Heart rate monitor |
Body composition | Body composition analyzer (BMI, MM, LBM) |
Hematological and biochemical parameters | Blood biochemical automatic analyzer (SPOZ) |
CT imaging | CT scanner |
Number | Search Terms of Query |
---|---|
#1 | COVID-19[Mesh] OR COVID-2019[tiab] OR COVID19[tiab] OR COVID-19 pandemic[tiab] OR COVID-19 virus disease[tiab] OR SARS-CoV-2 infection[tiab] OR 2019 novel coronavirus infection[tiab] OR coronavirus disease 2019[tiab] OR 2019-nCoV infection[tiab] OR COVID-19 virus infection[tiab] |
#2 | severe acute respiratory syndrome coronavirus 2[Mesh] OR SARS-CoV-2[tiab] OR 2019-nCoV[tiab] OR 2019 novel coronavirus[tiab] OR COVID-19 virus[tiab] OR COVID19 virus[tiab] OR coronavirus disease 2019 virus[tiab] OR Corona Virus Disease 2019[tiab] |
#3 | #1 OR #2 |
#4 | Pulmonary[Mesh] OR pulmonary rehabilitation[tiab] OR lung rehabilitation[tiab] OR pulmonary rehabilitation exercise[tiab] OR pulmonary recovery[tiab] OR lung recovery[tiab] OR lung rehabilitation exercise[tiab] OR pulmonary rehabilitation therapy[tiab] |
#5 | Respiratory therapy[Mesh] OR pulmonary respiratory therapy[tiab] OR breathing therapy[tiab] OR respiratory muscle training[tiab] OR respiratory muscle exercise[tiab] OR inspiratory muscle training[tiab] OR lung respiratory therapy[tiab] |
#6 | #4 OR #5 |
#7 | #3 AND #6 |
#8 | randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR clinical trials as topic[Mesh] OR trial[tiab] |
#9 | #7 AND #8 |
Bibliographic | Authors | Reported conflict of interest |
Title | Study design | |
Year of publication | Country | |
Journal | Setting(s) | |
Sources of funding | Type of allocation sequence | |
Institutions and affiliations | Inclusion and exclusion criteria | |
Demographics | Age | Severity of COVID-19 |
Sex | Stage of disease | |
Sample size | With or without complications | |
Description of health status | ||
Physical activity levels | ||
Pulmonary rehabilitation protocol | Pulmonary rehabilitation modalities (e.g., telerehabilitation, face to face, self-management) | Rehabilitation intensity |
Pulmonary rehabilitation program (e.g., aerobic exercise, resistance exercise, nutrition, education) | Rehabilitation session volume (total time of work and recovery intervals) | |
Duration, intensity, and modality | ||
Exercise modality (e.g., treadmill, stationary cycle) | Pulmonary rehabilitation combined with other interventions (e.g., combination of group psychological intervention and pulmonary rehabilitation) | |
Number and duration of work/recovery intervals | ||
Control intervention | ||
Pulmonary function | Time points measured | Pulmonary function levels at baseline and after pulmonary rehabilitation |
Time points reported | Pulmonary function levels at baseline and after follow-up | |
Follow-up time | ||
Measurement method | ||
Unit of measurement | ||
Exercise capacity | Time points measured | Exercise capacity at baseline and after pulmonary rehabilitation |
Time points reported | Exercise capacity at baseline and after follow-up | |
Follow-up time | ||
Measurement method | ||
Unit of measurement | ||
Dyspnea | Time points measured | Dyspnea levels at baseline and after pulmonary rehabilitation |
Time points reported | Dyspnea levels at baseline and after follow-up | |
Follow-up time | ||
Types of questionnaires | ||
Questionnaire scoring rules | ||
Health-related quality of life | Time points measured | Quality-of life-levels at baseline and after pulmonary rehabilitation |
Time points reported | Quality-of-life levels at baseline and after follow-up | |
Follow-up time | ||
Types of questionnaires | ||
Questionnaire scoring rules | ||
Other variables | Days in the hospital | Adverse effects (e.g., reasons for dropout, dizziness) |
Strength and endurance | Recruitment, retention, adherence, outcome rates, and acceptability of intervention | |
Sleep disorders | ||
Fatigue | ||
Blood pressure | ||
Body composition | ||
Hematological and biochemical parameters |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gao, Y.; Huang, H.; Ni, C.; Feng, Y.; Dong, X.; Wang, Y.; Yu, J. Pulmonary Rehabilitation in Patients with COVID-19—A Protocol for Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health 2022, 19, 13982. https://doi.org/10.3390/ijerph192113982
Gao Y, Huang H, Ni C, Feng Y, Dong X, Wang Y, Yu J. Pulmonary Rehabilitation in Patients with COVID-19—A Protocol for Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health. 2022; 19(21):13982. https://doi.org/10.3390/ijerph192113982
Chicago/Turabian StyleGao, Yanan, Huiming Huang, Chunxia Ni, Yong Feng, Xiao Dong, Yin Wang, and Junwu Yu. 2022. "Pulmonary Rehabilitation in Patients with COVID-19—A Protocol for Systematic Review and Meta-Analysis" International Journal of Environmental Research and Public Health 19, no. 21: 13982. https://doi.org/10.3390/ijerph192113982